ODYSSEY GROUP INTL INC - ODYY STOCK NEWS

Odyssey Group International has announced that its VP of Drug Development, Jake VanLandingham, along with NFL legends Brett Favre, Kurt Warner, and Mark Rypien, will appear on Banfield on July 27, 2021, at 10:00 pm ET.

They will discuss the urgent need for a treatment for concussion, highlighting PRV-002, a neurosteroid candidate. Recent studies indicate that 15% of individuals with concussions face long-term health issues. The Murdoch Children's Research Institute reported that 1/3 of youth who sustain concussions develop mental health issues, underscoring the need for effective therapies.

Odyssey Group International, Inc. (OTCQB: ODYY) announced it will hold its Annual Meeting of Stockholders in September 2021. Stockholder proposals must be submitted by August 5, 2021, to be considered. The company focuses on developing life-saving medical products and aims to acquire distinct assets and technologies for medical solutions. A Notice of Annual Meeting and Proxy Statement will be filed with the SEC after reviewing stockholder proposals. Forward-looking statements highlight potential risks and uncertainties affecting future performance.

Odyssey Group International (OTCQB: ODYY) announced the successful completion of final safety studies and cellular safety assays for its drug PRV-002, aimed at treating concussions. With a favorable review indicating no significant cardiac risk or mutagenesis, the drug is set for a final safety evaluation by the Clinical Trial Ethics Committee before human trials begin. The nasal applicator device met quality control standards, showing no contamination. PRV-002 has shown promising preclinical results, indicating potential neuroprotective effects and ability to address brain injury symptoms.

Odyssey Group International, Inc. (OTCQB: ODYY) announced that CEO Michael Redmond and Executive VP Dr. Jake VanLandingham will present at the 2021 LD Micro Invitational XI Investor Conference. The presentation is scheduled for June 10, 2020, from 11:00-11:30 am EDT. They will discuss the company's strategy for developing and acquiring life-saving medical products, including drug candidate PRV-002, aimed at treating concussions. Odyssey's mission focuses on creating distinct assets and technologies that enhance medical solutions.

Odyssey Group International (OTCQB: ODYY) announced the completion of a novel nano-particle drug formulation designed to enhance brain distribution of PRV-002, aimed at treating concussions. This formulation, paired with a proprietary nasal device, is expected to improve drug delivery directly to the brain, reducing systemic exposure and side effects. Clinical trials are set to begin this summer. The drug has shown promising neuroprotective effects in preclinical studies, with potential benefits in reducing oxidative stress and inflammation.

Odyssey Group International (OTCQB: ODYY) announced a significant milestone in developing its concussion drug, PRV-002. The completion of FDA-required toxicology studies has set the stage for a Phase 1 clinical trial, contracted with Nucleus Network in Australia. Preclinical studies suggest PRV-002 has a safety margin over 100-fold the intended dosing, preparing the company for clinical trials this summer. The data will support their Investigational New Drug Application (IND) with the FDA, paving the way for future Phase 2 trials in the US.

Odyssey Group International, Inc. (OTCQB: ODYY) has announced its Annual Meeting of Stockholders scheduled for June 30, 2021. Stockholders must submit proposals by June 3, 2021, to be considered at the meeting. The official Notice of Annual Meeting and Proxy Statement will be filed with the SEC after the Board reviews any received proposals. Odyssey is dedicated to developing life-saving medical products and aims to create distinct assets and technologies to deliver significant medical solutions and returns for shareholders.

Odyssey Group International has announced the successful development of a novel nasal drug delivery device for its concussion treatment candidate, PRV-002. Collaborating with Design Catapult, Inc., the device aims to enhance drug bio-distribution to the brain. It is set for use in phase 1 clinical trials scheduled in Australia this summer. Odyssey's CEO, Michael Redmond, highlights this milestone as crucial for administering PRV-002. The device has completed validation and will be manufactured under Good Manufacturing Practices.

Odyssey Group International, Inc. (OTCQB: ODYY) announced the appointment of Ricky Richardson to its Board of Directors. With over 30 years in operations and quality management, Richardson's previous roles include Corporate Director at Danaher Corporation and Director of Operations at Stryker Orthopaedics. His extensive experience in R&D and quality control is expected to enhance Odyssey's product development efforts, contributing to their mission of creating innovative medical solutions. The company focuses on leveraging technological advantages in the medical field.